Scholarlink

Introduction <p>Alopecia is a rare adverse reaction during tuberculosis (TB) treatment. Both drug-resistant TB and isoniazid (INH)-induced alopecia have been reported. We present this case because INH monoresistance coexisting with INH-induced alopecia has not previously been described in the literature.</p> Case <p>A 22-year-old woman was diagnosed with pulmonary TB and initiated on antituberculosis treatment (ATT). After 1 month, she developed sudden, severe hair loss. INH was suspected as the causative agent and discontinued. Hair regrowth was observed within 1 month. Drug resistance testing revealed INH monoresistance. Treatment was continued with rifampicin (R), pyrazinamide, ethambutol (E), and moxifloxacin for 2 months, followed by R and E for 7 months.</p> Conclusion <p>Clinicians should be vigilant for alopecia in young female patients receiving ATT, as it may lead to treatment interruption for cosmetic reasons. Alopecia may also signal underlying drug resistance, and further studies are needed to establish biological evidence for this association.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Isoniazid-induced alopecia in isoniazid-monoresistant pulmonary tuberculosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月31日

查看全文
  • Emine Afşin,
  • Şeref Özkara,
  • Fatma Ceren Gökdemir

摘要

Introduction

Alopecia is a rare adverse reaction during tuberculosis (TB) treatment. Both drug-resistant TB and isoniazid (INH)-induced alopecia have been reported. We present this case because INH monoresistance coexisting with INH-induced alopecia has not previously been described in the literature.

Case

A 22-year-old woman was diagnosed with pulmonary TB and initiated on antituberculosis treatment (ATT). After 1 month, she developed sudden, severe hair loss. INH was suspected as the causative agent and discontinued. Hair regrowth was observed within 1 month. Drug resistance testing revealed INH monoresistance. Treatment was continued with rifampicin (R), pyrazinamide, ethambutol (E), and moxifloxacin for 2 months, followed by R and E for 7 months.

Conclusion

Clinicians should be vigilant for alopecia in young female patients receiving ATT, as it may lead to treatment interruption for cosmetic reasons. Alopecia may also signal underlying drug resistance, and further studies are needed to establish biological evidence for this association.